What Investors are Making of These Biotech Stocks? - ChemoCentryx, Alder Biopharma, Neothetics, and OvaScience

Jun 28, 2016, 07:40 ET from Chelmsford Park SA

NEW YORK, June 28, 2016 /PRNewswire/ --

Economic uncertainty and pricing pressures remain the Biotech industry's biggest threats, but despite the challenges, several companies continue to impress. Ahead of today's session, Stock-Callers.com has issued alerts on the following equities: ChemoCentryx Inc. (NASDAQ: CCXI), Alder Biopharmaceuticals Inc. (NASDAQ: ALDR), Neothetics Inc. (NASDAQ: NEOT), and OvaScience Inc. (NASDAQ: OVAS). Learn more about these stocks and receive your complimentary trade alerts at:


To access Stock-Callers.com full PDF Research Packages for free, please visit the links below.



(You may have to copy and paste the links into your browser)

CCXI Research Package: http://stock-callers.com/registration/?symbol=CCXI

ALDR Research Package: http://stock-callers.com/registration/?symbol=ALDR

NEOT Research Package: http://stock-callers.com/registration/?symbol=NEOT

OVAS Research Package: http://stock-callers.com/registration/?symbol=OVAS


Mountain View, California headquartered clinical-stage biopharmaceutical Company ChemoCentryx Inc.'s stock finished Monday's session 2.90% lower at $4.36 and with a total volume of 196,080 shares traded. The Company's shares have advanced 81.67% over the previous three months. The stock is trading above its 50-day moving average by 11.47%. Furthermore, shares of ChemoCentryx, which focuses on the discovery, development, and commercialization of orally administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders, and cancer in the U.S., have a Relative Strength Index (RSI) of 46.37.

On Monday, shares in Bothell, Washington headquartered clinical-stage biopharmaceutical Company, Alder Biopharmaceuticals Inc. ended the session at $22.92, down 6.45%. The stock recorded a trading volume of 934,757 shares. The Company's shares are trading 16.92% below their 50-day moving average. Moreover, shares of Alder Biopharmaceuticals Bothell, which discovers, develops, and commercializes therapeutic antibodies in the U.S. and Australia, have an RSI of 30.25.

San Diego, California headquartered clinical-stage specialty pharmaceutical Company Neothetics Inc.'s stock ended yesterday's session 0.93% higher at $0.98 with a total volume of 127,453 shares traded. The Company's shares have advanced 58.58% in the previous three months. The stock is trading 8.31% below its 50-day moving average. Additionally, shares of Neothetics, which develops therapeutics for the aesthetic market, have an RSI of 40.48.

At the close on Monday, shares in Waltham, Massachusetts-based fertility Company, OvaScience Inc. recorded a trading volume of 856,091 shares, above their three months average volume of 563,610 shares. The stock finished 5.56% lower at $4.76. The Company's shares are trading below their 50-day moving average by 37.47%. Furthermore, shares of OvaScience, which discovers, develops, and commercializes new fertility treatment options for women globally, have an RSI of 28.86.


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: info@stock-callers.com Phone number:  +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA